Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 11/20 | 0.33 |
| ▸ | DRD2 | P14416 | 9/20 | 0.33 |
| ▸ | DRD1 | P21728 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442832 | 0.89 | DRD2 (0.31) | DRD3DRD2DRD1ALDH1A1KDM4E | |
| SCHEMBL6448961 | 0.85 | DRD2 (0.35) | DRD3DRD2DRD1ALDH1A1KDM4E | |
| SCHEMBL8559498 | 0.79 | — | — | |
| SCHEMBL21555966 | 0.79 | — | — | |
| SCHEMBL6442272 | 0.75 | — | — | |
| SCHEMBL8863480 | 0.74 | GBA2 (0.38) | MAPK1 | |
| SCHEMBL6445513 | 0.74 | DRD2 (0.33) | DRD3DRD2DRD1ALDH1A1KDM4E | |
| Ethane SCHEMBL28461232 | 0.73 | PDK1 (0.35) | DRD3DRD2DRD1ALDH1A1KDM4E | |
| SCHEMBL6444394 | 0.73 | — | — | |
| SCHEMBL12601745 | 0.72 | DRD2 (0.32) | DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537158-B1 | RADIATION CURED POLYURETHANES WITH CAPPED AMINO GROUPS | BASF SE (DE) | 2013-04-24 | — | — | EP | disclosed |
| EP-1981859-B1 | PREPARATION OF DELMOPINOL | SINCLAIR PHARMACEUTICALS LTD (GB) | 2012-10-31 | — | — | EP | disclosed |
| US-8093398-B2 | Preparation of delmopinol | Sinclair Pharmaceticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20110082301-A1 | Preparation of Delmopinol | COMELY ALEXANDER | 2011-04-07 | — | — | US | disclosed |
| US-7893258-B2 | Preparation of delmopinol | SINCLAIR PHARMACEUTICALS LIMITED (GB) | 2011-02-22 | — | — | US | disclosed |
| US-20090036677-A1 | Preparation of Delmopinol | MAELOR LABORATORIES LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| EP-1981859-A2 | PREPARATION OF DELMOPINOL | Sinclair Pharmaceuticals Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007091009-A2 | PREPARATION OF DELMOPINOL | SINCLAIR PHARMACEUTICALS LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| US-20050244652-A1 | Radiation curable polyurethanes with capped amino groups | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-03 | — | — | US | disclosed |
| EP-1537158-A1 | RADIATION CURED POLYURETHANES WITH CAPPED AMINO GROUPS | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022621-A1 | RADIATION CURED POLYURETHANES WITH CAPPED AMINO GROUPS | BASF AKTIENGESELLSCHAFT (DE) | 2004-03-18 | — | — | WO | disclosed |
| US-5473043-A | Waterproofing protective coating comprising a polyetherurethane copolymer, a blocked amine containing two hydrolyzable oxazolidene rings and an inorganic filler; storage stability; one-package | DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) | 1995-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082301-A1 | Preparation of Delmopinol | CBR3, AVPR2, C1S | DRD3 13/4885DRD2 42/4885DRD1 40/4885 |
| US-20090036677-A1 | Preparation of Delmopinol | AVPR2, CBR3, C1S | DRD3 10/4885DRD2 38/4885DRD1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.